1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Engineered biosynthesis of plant heteroyohimbine and corynantheine alkaloids in Saccharomyces cerevisiae

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

           

          Monoterpene indole alkaloids (MIAs) are a class of natural products comprised of thousands of structurally unique bioactive compounds with significant therapeutic values. Due to difficulties associated with isolation from native plant species and organic synthesis of these structurally complex molecules, microbial production of MIAs using engineered hosts are highly desired. In this work, we report the engineering of fully integrated Saccharomyces cerevisiae strains that allow de novo access to strictosidine, the universal precursor to thousands of MIAs at 30–40 mg/L. The optimization efforts were based on a previously reported yeast strain that is engineered to produce high titers of the monoterpene precursor geraniol through compartmentalization of mevalonate pathway in the mitochondria. Our approaches here included the use of CRISPR-dCas9 interference to identify mitochondria diphosphate transporters that negatively impact the titer of the monoterpene, followed by genetic inactivation; the overexpression of transcriptional regulators that increase cellular respiration and mitochondria biogenesis. Strain construction included the strategic integration of genes encoding both MIA biosynthetic and accessory enzymes into the genome under a variety of constitutive and inducible promoters. Following successful de novo production of strictosidine, complex alkaloids belonging to heteroyohimbine and corynantheine families were reconstituted in the host with introduction of additional downstream enzymes. We demonstrate that the serpentine/alstonine pair can be produced at ∼5 mg/L titer, while corynantheidine, the precursor to mitragynine can be produced at ∼1 mg/L titer. Feeding of halogenated tryptamine led to the biosynthesis of analogs of alkaloids in both families. Collectively, our yeast strain represents an excellent starting point to further engineer biosynthetic bottlenecks in this pathway and to access additional MIAs and analogs through microbial fermentation.

          One Sentence Summary

          An Saccharomyces cerevisiae-based microbial platform was developed for the biosynthesis of monoterpene indole alkaloids, including the universal precursor strictosidine and further modified heteroyohimbine and corynantheidine alkaloids.

          Graphical Abstract

          Graphical Abstract

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: not found

          Production of the antimalarial drug precursor artemisinic acid in engineered yeast.

          Malaria is a global health problem that threatens 300-500 million people and kills more than one million people annually. Disease control is hampered by the occurrence of multi-drug-resistant strains of the malaria parasite Plasmodium falciparum. Synthetic antimalarial drugs and malarial vaccines are currently being developed, but their efficacy against malaria awaits rigorous clinical testing. Artemisinin, a sesquiterpene lactone endoperoxide extracted from Artemisia annua L (family Asteraceae; commonly known as sweet wormwood), is highly effective against multi-drug-resistant Plasmodium spp., but is in short supply and unaffordable to most malaria sufferers. Although total synthesis of artemisinin is difficult and costly, the semi-synthesis of artemisinin or any derivative from microbially sourced artemisinic acid, its immediate precursor, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin. Here we report the engineering of Saccharomyces cerevisiae to produce high titres (up to 100 mg l(-1)) of artemisinic acid using an engineered mevalonate pathway, amorphadiene synthase, and a novel cytochrome P450 monooxygenase (CYP71AV1) from A. annua that performs a three-step oxidation of amorpha-4,11-diene to artemisinic acid. The synthesized artemisinic acid is transported out and retained on the outside of the engineered yeast, meaning that a simple and inexpensive purification process can be used to obtain the desired product. Although the engineered yeast is already capable of producing artemisinic acid at a significantly higher specific productivity than A. annua, yield optimization and industrial scale-up will be required to raise artemisinic acid production to a level high enough to reduce artemisinin combination therapies to significantly below their current prices.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method.

            Here we describe a high-efficiency version of the lithium acetate/single-stranded carrier DNA/PEG method of transformation of Saccharomyces cerevisiae. This method currently gives the highest efficiency and yield of transformants, although a faster protocol is available for small number of transformations. The procedure takes up to 1.5 h, depending on the length of heat shock, once the yeast culture has been grown. This method is useful for most transformation requirements.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications.

              A set of yeast strains based on Saccharomyces cerevisiae S288C in which commonly used selectable marker genes are deleted by design based on the yeast genome sequence has been constructed and analysed. These strains minimize or eliminate the homology to the corresponding marker genes in commonly used vectors without significantly affecting adjacent gene expression. Because the homology between commonly used auxotrophic marker gene segments and genomic sequences has been largely or completely abolished, these strains will also reduce plasmid integration events which can interfere with a wide variety of molecular genetic applications. We also report the construction of new members of the pRS400 series of vectors, containing the kanMX, ADE2 and MET15 genes.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Ind Microbiol Biotechnol
                J Ind Microbiol Biotechnol
                jimb
                Journal of Industrial Microbiology & Biotechnology
                Oxford University Press
                1367-5435
                1476-5535
                2024
                22 December 2023
                22 December 2023
                : 51
                : kuad047
                Affiliations
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Bioengineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Stanford Genome Technology Center, Stanford University , Stanford, CA  94305, USA
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Molecular Cell and Developmental Biology, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Bioengineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology , Jena  07745, Germany
                Department of Chemical and Biomolecular Engineering, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Department of Chemistry and Biochemistry, University of California, Los Angeles , Los Angeles, CA  90095, USA
                Author notes
                Correspondence should be addressed to: Yi Tang, Tel: +1-(310) 825-0375. Email: yitang@ 123456g.ucla.edu
                Author information
                https://orcid.org/0000-0003-1597-0141
                Article
                kuad047
                10.1093/jimb/kuad047
                10995622
                38140980
                5e8380ef-794f-4251-af58-71ec5ce9d418
                © The Author(s) 2023. Published by Oxford University Press on behalf of Society of Industrial Microbiology and Biotechnology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 09 November 2023
                : 21 December 2023
                : 09 January 2024
                Page count
                Pages: 12
                Funding
                Funded by: National Institutes of Health, DOI 10.13039/100000002;
                Award ID: 1R01AT010001
                Funded by: National Science Foundation, DOI 10.13039/100000001;
                Award ID: 1933487
                Funded by: University of California, Los Angeles, DOI 10.13039/100007185;
                Categories
                Original Paper
                Metabolic Engineering and Synthetic Biology
                Jimb/7
                AcademicSubjects/SCI01150
                AcademicSubjects/SCI00540
                Editor's Choice

                Biotechnology
                metabolic engineering,monoterpene indole alkaloids,strictosidine,microbial production,saccharomyces cerevisiae

                Comments

                Comment on this article